Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

2020 Year in Review - Breast Cancer - Breast Cancer

In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators.

In the MONARCH 2 study, abemaciclib, an oral selective CDK4/6 inhibitor, plus fulvestrant demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared with placebo plus fulvestrant in hormone receptor–positive, HER2-negative advanced breast cancer. Numerically more pronounced improvement in PFS and OS was noted in subgroups with visceral disease and primary endocrine resistance.

Patrick Neven, MD, PhD, Oncologist, Gynecologic Oncology, University Hospital Leuven, Belgium, and colleagues reported PFS and OS for MONARCH 2 with respect to first- and second-line treatment outcomes.

This was an international, randomized, double-blind phase 3 trial of abemaciclib and fulvestrant (N = 446) or placebo and fulvestrant (N = 223) in women with endocrine therapy–resistant, hormone receptor–positive, HER2-negative advanced breast cancer regardless of menopausal status. Stratification of patients was conducted by resistance to previous endocrine therapy (primary vs secondary) and site of metastasis (visceral, bone-only, or other).

In 2019, at the time of data cutoff, the effect of abemaciclib and fulvestrant compared with placebo and fulvestrant was consistent across first-line therapy and second-line therapy. The subanalysis revealed no statistically significant impact on PFS (P = .341) or OS (P = .265). For patients receiving it as first-line therapy, improvement in PFS was demonstrated (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.45-0.73); within this population, there was also a positive impact on OS (HR, 0.85; 95% CI, 0.64-1.14). In the second-line therapy setting, efficacy was similar as shown in data from PFS (HR, 0.48; 95% CI, 0.36-0.64) as well as OS (HR, 0.66; 95% CI, 0.46-0.94).

The most profound effects were shown in the first-line therapy population in which patients had less favorable prognostic indicators, such as primary endocrine therapy resistance (PFS: HR, 0.40; 95% CI, 0.26-0.63; OS: HR, 0.58; 95% CI, 0.35-0.97) and visceral disease (PFS: HR, 0.54; 95% CI, 0.39-0.73; OS: HR, 0.82; 95% CI, 0.57-1.17).

The investigators concluded that, in the MONARCH 2 study, the observed statistically significant benefit was across first- and second-line therapy patients. In patients treated with abemaciclib and fulvestrant in the first-line therapy setting, improvements were observed for PFS and OS with profound effects noted in patients with resistance to primary endocrine therapy and visceral disease.

Source: Neven P, Johnston SRD, Toi M, et al. MONARCH 2: subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer. J Clin Oncol. 2020;38(15_suppl). Abstract 1061.

Related Items
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape published on January 11, 2024 in Breast Cancer
Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
Emily M. Beard, RN, BSN, OCN, CBCN, Abbey J. Kaler, MS, APRN, FNP-C, Mohammed A. Jaloudi, MD
Best Practices in Ovarian Function Suppression in Breast Cancer published on December 21, 2023 in Breast Cancer
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: